Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 26.27 -3.98% -1.09
ACAD closed down 3.98 percent on Thursday, May 25, 2017, on 3 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ACAD trend table...

Date Alert Name Type % Chg
May 25 Reversal New Lows Setup Bearish Swing Setup 0.00%
May 25 Expansion Breakdown Bearish Swing Setup 0.00%
May 23 1,2,3 Retracement Bearish Bearish Swing Setup -4.65%
May 23 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.65%
May 22 NR7 Range Contraction -6.21%
May 19 Slingshot Bearish Bearish Swing Setup -5.67%
May 17 New Downtrend Bearish -2.92%
May 17 Lower Bollinger Band Walk Other -2.92%
May 16 Lower Bollinger Band Walk Other -7.50%
May 15 Lower Bollinger Band Walk Other -7.92%

Older signals for ACAD ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Is ACAD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 42.49
52 Week Low 20.68
Average Volume 74,283,523
200-Day Moving Average 31.3703
50-Day Moving Average 32.4298
20-Day Moving Average 29.9155
10-Day Moving Average 27.735
Average True Range 1.1561
ADX 34.51
+DI 11.06
-DI: 36.77
Chandelier Exit (Long, 3 ATRs) 31.7517
Chandelier Exit (Short, 3 ATRs) 29.5183
Upper Bollinger Band 35.0622
Lower Bollinger Band 24.7688
Percent B (%b) 0.15
Bandwidth 0.344082
MACD Line -1.7122
MACD Signal Line -1.5098
MACD Histogram -0.2024